Site Selection magazine
twitter linkedIn facebook email email
TRANSLATE: 
PHARMACEUTICALS
A Site Selection Web Exclusive, December 2013
SHARE THIS ON SOCIAL MEDIA
WEB Exclusive story

Restocking the Medicine Chest

New Jersey’s appeal as a headquarters location continues, for small and large firms alike.

PHARMACEUTICALS
New Jersey’s life sciences leadership includes education at universities and at public institutions such as the Liberty Science Center, a 300,000-sq.-ft. learning center located in Liberty State Park on the Jersey City bank of the Hudson near the Statue of Liberty. Here, thanks to sponsorship from such companies as Pfizer, BD and Lysol, visitors to the “Infection Connection” exhibition explore the connections between humans and microbes and emerging diseases, and discover how science develops tools and technologies to prevent and treat infections.
Photo courtesy of Liberty Science Center

by ADAM BRUNS
W
Phil Blake, Bayer Corp. president, applauds New Jersey Gov. Chris Christie (r.) at the October 2013 grand opening of Bayer HealthCare’s newly consolidated 2,400-employee HQ in Whippany, N.J., in Hanover Township. Seated alongside Christie is Marijn Dekkers, chairman of the board for Bayer AG.
Phil Blake, Bayer Corp. president, applauds New Jersey Gov. Chris Christie (r.) at the October 2013 grand opening of Bayer HealthCare’s newly consolidated 2,400-employee HQ in Whippany, N.J., in Hanover Township. Seated alongside Christie is Marijn Dekkers, chairman of the board for Bayer AG.
Photo courtesy of Gov. Christie’s office

hen New Jersey Gov. Chris Christie in September signed into law the New Jersey Economic Opportunity Act, streamlining the state’s incentive programs to two, he did so on the heels of two ribbon-cuttings. One was for Panasonic at its Newark facility, and the other was celebrating the less ballyhooed first anniversary of Zoetis (formerly Pfizer Animal Health), which in 2012 chose Florham Park for its headquarters.

“We are committed to growing our business in New Jersey where we have access to a highly educated and diverse work force, which is essential to managing a global animal health company,” said Sandra J. Beaty, executive vice president, corporate affairs at Zoetis. “We want to thank Governor Chris Christie, Lieutenant Governor Kim Guadagno, and their administration for all their efforts to help create a favorable business climate in the state. We are proud to call New Jersey our home.”

“The decision by Zoetis to locate its global headquarters in New Jersey is further confirmation of New Jersey being not only an international center of excellence for the life science industries but also a growing hub for the animal health sector,” said Gov. Christie, noting that three of the leading global animal health companies call the Garden State home.

The New Jersey Economic Development Authority awarded Zoetis a Business Employment Incentive Program Grant of $19 million on Aug. 14, 2012. Under the terms of the grant, Zoetis has located approximately 400 employees at its 100 Campus Drive headquarters in Florham Park. The property is owned by KBS Real Estate Investment Trust II and managed by CBRE. Employees there support the company’s global business functions and its marketing and veterinary technical services operations in the United States and the Canada-Latin America region.

Zoetis, a $4.3-billion company with 9,300 employees worldwide, derives its name from the word “zoetic,” meaning “pertaining to life.” And the signs since the fall continue to indicate that New Jersey’s reputation as the “world’s medicine chest” is well earned.

On Dec. 11, the Board of the New Jersey Economic Development Authority (EDA) approved a significant Grow NJ award for Valeant Pharmaceuticals International, Inc. to incent the company to remain and grow in New Jersey. Valeant, which recently acquired Bausch & Lomb, whose core businesses include ophthalmic pharmaceuticals, was approved for a Grow NJ award of up to $39,502,500 over ten years to locate its combined US headquarters in New Jersey. The Bridgewater site is currently undergoing renovations and would ultimately house a combined work force of over 800 employees, with 274 retained positions and 550 new full-time jobs. Headquartered in Laval, Quebec, Valeant has approximately 15,000 employees worldwide

“The Grow New Jersey program is designed to make New Jersey an even more attractive prospect for corporations making major decisions about remaining or relocating here,” said EDA CEO Michele Brown. “The prospect of Valeant locating its combined U.S. headquarters here is exciting and important for our state. With the Board’s approval, New Jersey can help the company remain, thrive and grow in New Jersey.”

Both Valeant and Bausch & Lomb have existing Business Employment Incentive Program (BEIP) agreements provided by the EDA in 2003 and 2008, respectively. The company has reached an agreement with the EDA to end the existing grant agreements and use a sliding-scale recapture for a portion of the payments that are due. The modification was approved at a December EDA board meeting.

“We are committed to growing our business in New Jersey where we have access to a highly educated and diverse work force, which is essential to managing a global animal health company.”

— Sandra J. Beaty, executive vice president,corporate affairs, Zoetis

Grow New Jersey is now the state’s main job incentive program. The enhanced program will support businesses looking to grow throughout the state and provide New Jersey with a more effective tool to spur job growth in targeted areas. As the EDA explains, to enable smaller businesses to qualify for incentives, the revised Grow NJ program expands geographic boundaries within which businesses can qualify for assistance and lowers capital investment and employment eligibility requirements. By lowering eligibility thresholds, more small and mid size businesses can now be assisted.

Four additional projects were also approved under the revised Grow NJ Assistance program. With Valeant’s Grow NJ award, these projects, located in Camden, Neptune, Newark and Jersey City, are slated to receive a total of approximately $92.9 million tied to the creation of 900 new, full-time jobs and the retention of more than 925 existing full-time New Jersey jobs at risk of being located outside the state. 

The revised programs place extra emphasis on spurring development and private sector job growth in certain smart growth areas, distressed municipalities and transit oriented locations and in certain targeted areas, such as "Garden State Growth Zones" identified in the Act as the cities with the four lowest median family incomes: Camden, Trenton, Passaic City and Paterson.

Biotech Boost

Also this month, the EDA announced that 54 companies have been approved to share the $60 million allocation available through the State’s Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2014.

The program enables technology and biotechnology companies to sell New Jersey tax losses and/or R&D tax credits to raise cash to finance their growth and operations. Since the program was established in 1999, more than 490 different businesses have been approved for awards totaling $770 million. Each of the 54 applicants approved this year will receive an estimated $1.1 million, which is a 21-percent increase from last year. 

"The NOL Program continues to be the most popular and the most effective support for these early-stage companies,” said EDA’s Michele A. Brown. “These companies have been able to raise capital and build their businesses in New Jersey as a result of this innovative program. This is exactly the kind of vital support this sector needs.”

Under the program, administered by the EDA and the Department of Treasury's Division of Taxation, New Jersey-based technology or biotechnology companies with fewer than 225 US employees may be eligible to sell net operating losses and research and development tax credits to unrelated profitable corporations for at least 80 percent of their value, up to a maximum lifetime benefit of $15 million per business.

Companies that benefited this year include:

  • New Brunswick-based Connotate, Inc., a tech company whose aim is to be the best in the world at Web data extraction and monitoring
  • Princeton Power Systems in Princeton, a designer and manufacturer of technology products for energy management, micro-grid operations and electric vehicle charging
  • Eagle Pharmaceuticals, a Woodcliff Lake-based pharmaceutical company which develops improved formulations of injectable products. Eagle has a development portfolio in excess of 15 products and currently has one marketed drug.

The state’s role as part of the Greater Philadelphia economy even helps researchers in the field garner funds from entities outside state lines: Also early this month, Philadelphia’s University City Science Center’s QED Proof-of-Concept program awarded a total of $600,000 to life science and health IT researchers from Drexel University, Temple University and Rutgers, The State University of New Jersey, where Dr. Samuel Gunderson is validating a new therapeutic compound for pancreatic cancer. The QED Program was launched in April 2009. Twenty-two colleges, universities and research institutions in Pennsylvania, New Jersey, and Delaware participate under a common agreement that defines matching funds and intellectual property management.

The number of biotechnology companies operating in New Jersey increased from more than 300 in 2010 to more than 340 companies in 2012, an increase of more than 13 percent, and the number of employees increased from approximately 15,000 in 2010 to an estimated 16,400 in 2012, an increase of 9.3 percent, according to the results of an industry survey conducted by BioNJ, the trade association for the biotechnology industry in New Jersey, and Ernst &Young.

As the list below of NOL beneficiaries illustrates, the biotech pipeline in New Jersey continues to flow.

Company Name Industry City County
IGI Labs Inc. Biotech Buena Atlantic
MDX Medical, Inc. (dba Vitals, Inc.) Tech Lyndhurst Bergen
ADM Tronics Unlimited Inc. Tech Northvale Bergen
Elite Laboratories, Inc. Biotech Northvale Bergen
Millenium Biotechnologies Group, Inc. Biotech Paramus Bergen
DVTel, Inc. Tech Ridgefield Park Bergen
Cancer Genetics, Inc. Biotech Rutherford Bergen
Circulite Inc. Biotech Teaneck Bergen
Eagle Pharmaceuticals, Inc. Biotech Woodcliff Lake Bergen
I.D. Systems, Inc. Tech Woodcliff Lake Bergen
Ivy Sports Medicine LLC Biotech Montvale Bergen
Agilence Inc. Biotech Mount Laurel Burlington
Antenna Software, Inc. Tech Jersey City Hudson
Voxware, Inc. Tech Hamilton Mercer
Princeton Power Systems Tech Lawrenceville Mercer
Ocean Power Technologies, Inc. Tech Pennington Mercer
PD-LD Inc. Tech Pennington Mercer
Advaxis, Inc. Biotech Princeton Mercer
Agile Therapeutics Biotech Princeton Mercer
Midawi Holdings Tech Princeton Mercer
SightLogix, Inc. Tech Princeton Mercer
Soligenix, Inc. Biotech Princeton Mercer
World Water & Solar Technologies Tech Princeton Mercer
Alphion Corporation Tech Princeton Junction Mercer
Amicus Therapeutics, Inc. Biotech Cranbury Middlesex
Blacklight Power, inc. Tech Cranbury Middlesex
Palatin Technologies, Inc. Biotech Cranbury Middlesex
Cornerstone Pharmaceuticals Biotech Cranbury Middlesex
Oncobiologics Inc. Biotech Cranbury Middlesex
Replication Medical, Inc. Biotech Cranbury Middlesex
Vaxinnate Corporation Biotech Cranbury Middlesex
Savient Pharmaceuticals, Inc. Biotech East Brunswick Middlesex
Symbolic IO Corporation Tech Edison Middlesex
CytoSorbents, Inc. Biotech Monmouth Junction Middlesex
Insmed Incorporated Biotech Monmouth Junction Middlesex
Rive Technology, Inc. Tech Monmouth Junction Middlesex
TyRx Pharma, Inc. Biotech Monmouth Junction Middlesex
Liquid Light Tech Monmouth Junction Middlesex
Connotate Technologies, Inc. Tech New Brunswick Middlesex
Hemispherx Biopharma, Inc. Biotech New Brunswick Middlesex
Solidia Technologies Tech Piscataway Twp Middlesex
Innopharma, Inc. Biotech Piscataway Middlesex
iBiquity Digital Corporation Tech Piscataway Middlesex
Celator Pharmaceuticals, Inc. Biotech Plainsboro Middlesex
Angel Medical Systems, Inc. Biotech Shrewsbury Monmouth
Emisphere Technologies, Inc. Tech Cedar Knolls Morris
DataMotion, Inc. Tech Morristown Morris
Aerie Pharmaceuticals, Inc. Biotech Bedminster Somerset
Conolog Corporation Tech Branchburg Somerset
VPI Systems Corporation Tech Somerset Somerset
Roka Bioscience, Inc. Biotech Warren Somerset
Edge Therapeutics Biotech New Providence Union
Svelte Medical Systems, Inc. Biotech New Providence Union
Celldex Research Corporation Biotech Phillipsburg Warren

comments powered by Disqus

The Site Selection Life Sciences Report features exclusive and in-depth reporting and analysis on the most important life science projects and issues. Topics covered include pharmaceutical R&D and manufacturing, biotechnology, medical device manufacturing, health-care services facility trends, clinical research and other key life science sectors.


i

Related Articles











i

Most Popular Articles










Site Selection online is a worldwide service of Conway, Inc. ©1983-2017, all rights reserved.
Data is from many sources and not warranted to be accurate or current.
For contact information visit our staff page or send general information queries to Cathie Wendt.
Send direct technical inquiries or comments to webmaster bounce@conway.com. View our Privacy Policy.
HOME | SITE SELECTION MAGAZINE ARCHIVES | SUBSCRIBE